Skip to content
Peptidepedia

KPV Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

The body of KPV research consists almost entirely of preclinical studies using cell culture and animal models. No large-scale human clinical trials have been completed.

Intestinal Inflammation: In the landmark 2008 Gastroenterology study, Dalmasso and colleagues demonstrated that KPV is transported into colonic cells via PepT1 and reduces DSS- and TNBS-induced colitis in mice. Oral KPV decreased pro-inflammatory cytokine expression and attenuated disease severity across multiple colitis models.

Colitis-Associated Cancer: A 2016 study in Cellular and Molecular Gastroenterology and Hepatology showed that KPV dramatically reduced colonic tumorigenesis in a mouse model of colitis-associated cancer. Tumor numbers, sizes, and overall burden were decreased in KPV-treated animals. This effect was abolished in PepT1-knockout mice, confirming PepT1 dependence.

Murine IBD Models: Kannengiesser and colleagues (2008) demonstrated that the melanocortin-derived tripeptide KPV had anti-inflammatory potential in two distinct murine models of inflammatory bowel disease, reducing colonic damage and inflammatory cytokine levels.

Nanoparticle Delivery: Xiao and colleagues (2017) developed hyaluronic acid-functionalized nanoparticles for oral KPV delivery. The HA-KPV-NPs achieved therapeutic efficacy at a 12,000-fold lower concentration than free KPV, while simultaneously accelerating mucosal healing and alleviating inflammation in a mouse model of ulcerative colitis.

Bronchial Inflammation: Research in human bronchial epithelial cells revealed the specific mechanism of KPV's NF-kB inhibition: nuclear import of KPV followed by competitive blocking of the Imp-alpha3/p65 interaction. This study also identified a role for MC3R agonists in melanocortin anti-inflammatory signaling.

Dermatological Research: Multiple studies have shown that KPV suppresses contact hypersensitivity in mouse models and induces hapten-specific tolerance. In keratinocyte cell cultures, KPV reduces inflammatory cytokine production and mitigates fine dust-induced cellular damage via MAPK/NF-kB pathway modulation.

Antimicrobial Activity: Alpha-MSH peptides, including KPV, have demonstrated antimicrobial effects against Staphylococcus aureus (including methicillin-resistant strains) and Candida albicans at physiological picomolar concentrations. A dimeric form ([Ac-CKPV]2) showed enhanced candidacidal activity.

Human Data: No registered clinical trials exist specifically for KPV. All evidence comes from in vitro and animal model studies, which do not guarantee equivalent effects or safety in humans.

Frequently Asked Questions

Preclinical research in animal models of colitis suggests KPV reduces intestinal inflammation by inhibiting NF-kB signaling and pro-inflammatory cytokine production. It is transported into intestinal cells by the PepT1 transporter, which is upregulated during inflammatory bowel disease. However, no human clinical trials have confirmed these effects.

Both peptides are researched for anti-inflammatory and gut-healing properties, but they work through different mechanisms. BPC-157 promotes angiogenesis and tissue regeneration via VEGF and growth factor pathways. KPV targets NF-kB signaling and pro-inflammatory cytokine suppression. They are sometimes stacked together for complementary effects.

There are no FDA-approved dosing guidelines. In research and community use, subcutaneous doses typically range from 200 to 500 mcg per day, while oral doses range from 500 to 1,500 mcg per day. Oral administration may be preferred for gastrointestinal applications due to PepT1-mediated uptake in the gut.

KPV has demonstrated a favorable safety profile in preclinical studies. Reported side effects are generally mild and may include injection site irritation, mild nausea, and occasional gastrointestinal discomfort. Unlike corticosteroids, KPV does not appear to suppress immune function broadly. Long-term human safety data are not available.

KPV is not FDA-approved for any medical indication and cannot legally be sold for human consumption. It is sold as a research chemical. As of early 2026, regulatory developments suggest KPV may be reclassified to allow compounding pharmacies to prepare it with a valid prescription, but formal rules have not been finalized.

Yes, unlike many peptides, KPV can be administered orally. Research demonstrates that it is actively transported into intestinal epithelial cells and immune cells via the PepT1 di/tripeptide transporter. Oral bioavailability is lower than injectable forms, but direct delivery to gut tissue may be advantageous for gastrointestinal conditions.

Preclinical studies show KPV suppresses contact hypersensitivity and dermatitis in animal models when applied topically or administered systemically. It reduces pro-inflammatory cytokines in keratinocytes and can induce hapten-specific tolerance. A U.S. patent exists for KPV use in dermatological disorders, but human clinical trials remain limited.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
  2. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.
  3. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640.
  4. Dalmasso G, Nguyen HTT, Yan Y, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357.
  5. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
  6. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73.
  7. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140.
  8. Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55.
  9. Catania A, Rajora N, Capsoni F, Minonzio F, Star RA, Lipton JM. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides. 1996;17(4):675-679.
  10. Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610.
  11. Yoon SW, Shin DH, Kim JS, et al. Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway. J Dermatol Sci. 2025.
←Read the full KPV guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”